Comparative Efficacy of Selected Vitamins (B9, B12, C, and D) on Cognitive Function in Parkinsons Disease.

Patients with Parkinsons disease are screened for eligibility based on diagnosis cognitive status MoCA less than 24 and medical exclusions including G6PD deficiency thalassemia liver or kidney disease ulcers and anemia Eligible participants provide informed consent and are assigned into five separate groups Group one receives standard care only Group two receives standard care with vitamin B9 Group three receives standard care with vitamin B12 Group four receives standard care with vitamin C Group five receives standard care with vitamin D

Baseline assessments include demographics vitals clinical history laboratory test such as Beta amyloid 40 and 42 ratio biomarker levels MoCA and Neuro QoL score scale Participants are monitored for adherence side effects and use of any additional medicines during the study

Follow up evaluations at baseline month three and month six include amyloid biomarker ratio cognitive function MoCA quality of life Neuro QoL and recording of adverse events After six months a final analysis is done to assess efficacy safety and improvement in quality of life